**
In a troubling revelation, internal records have disclosed that top officials from the Trump administration’s Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, last year to discuss legal strategies concerning the contentious glyphosate herbicide, which has been linked to cancer. This meeting, held on 17 June, occurred just months before significant actions were taken by the administration to bolster Bayer’s position in ongoing litigation involving thousands of individuals who allege their cancer diagnoses stem from glyphosate exposure.
Glyphosate Under Fire: The Legal Battle
The heart of the ongoing litigation against Bayer revolves around claims that the company has inadequately warned consumers about the cancer risks associated with its glyphosate-based products, most notably Roundup. With tens of thousands of lawsuits pending, Bayer has incurred staggering financial liabilities due to settlements and jury verdicts. The company is advocating for a legal argument that hinges on the premise that if the EPA does not mandate a cancer warning for glyphosate, Bayer cannot be held accountable for its failure to disclose potential risks.
This argument has seen mixed results in court. While a favourable ruling from one appellate court provided a temporary victory for Bayer, several others have rejected the preemption claim, including the Biden administration’s solicitor general. The current administration’s stance contrasts sharply with that of its predecessor, which actively sought to support Bayer’s legal strategy.
The Meeting: A Concerning Convergence
The 17 June meeting at the EPA has raised significant eyebrows, particularly given its timing and the subsequent actions taken by the Trump administration to support Bayer’s interests. Attendees included Lee Zeldin, the EPA administrator, and other high-ranking officials, who were briefed on Bayer’s litigation status and potential labelling strategies. According to an internal email from 13 June, the gathering was explicitly intended to address “legal/judicial issues,” including potential Supreme Court action.
Environmental advocates have expressed alarm over the implications of such high-level interactions. Nathan Donley, environmental health science director for the Center for Biological Diversity, highlighted that the meeting exemplifies the undue influence corporations wield over regulatory decisions that impact public health. “When corporate leaders can meet with political appointees in a government office, it underscores the power dynamics that compromise the health of everyday Americans,” he asserted.
Administration’s Support: A Pattern of Preference
Following the meeting, the Trump administration’s support for Bayer manifested in multiple ways. On 1 December, the solicitor general, appointed by the Trump administration, urged the Supreme Court to take up Bayer’s case, a request that was subsequently granted. Furthermore, the invocation of the Defence Production Act on 18 February facilitated the protection of glyphosate production and granted immunity to its manufacturers, including Bayer. An amicus brief filed on 2 March by the solicitor general further solidified the government’s backing for Bayer’s legal arguments.
Bayer has defended its meetings with EPA officials as routine aspects of the regulatory process, asserting their transparency regarding glyphosate litigation matters. However, critics argue that such interactions are not equally afforded to those affected by glyphosate, including the many individuals who have filed lawsuits.
The Disparity in Access to Power
Legal experts and advocates have voiced concerns about the implications of corporate meetings with government officials. Whitney Di Bona, a consumer safety advocate, remarked on the troubling nature of such private discussions aimed at limiting corporate liability without corresponding opportunities for public input or advocacy. Naomi Oreskes, a Harvard professor investigating corporate influence in regulatory practices, noted that this pattern of privileged access for industry leaders starkly contrasts with the lack of similar engagement for the general public.
Zen Honeycutt, founder of Moms Across America, expressed dismay but not surprise at the revelations, highlighting a long-standing trend of chemical companies exerting pressure on regulatory agencies. “The coercion by chemical companies on our regulatory agencies is nothing new,” she stated, underscoring the need for increased accountability and transparency within the EPA.
Why it Matters
The revelations surrounding the meeting between Bayer and EPA officials underscore a significant concern: the intersection of corporate interests and public health policy. As regulatory frameworks are shaped behind closed doors, the potential consequences for individuals affected by glyphosate are dire. The ongoing litigation represents not just a legal battle but a fight for transparency and accountability in how governmental agencies respond to corporate lobbying. The implications of such corporate influence extend far beyond Bayer, calling into question the integrity of regulatory processes designed to protect the health and safety of the public. As citizens, it is crucial to demand that our regulatory bodies prioritise public welfare over corporate profits.
